A5018736882- Cancer, Hypoxia, and Metabolism
- Estrogen and related hormone effects
- Cancer, Lipids, and Metabolism
- Cancer Cells and Metastasis
- Metabolism, Diabetes, and Cancer
- Epigenetics and DNA Methylation
- MicroRNA in disease regulation
- RNA modifications and cancer
- Cancer-related Molecular Pathways
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Nuclear Receptors and Signaling
- Immune cells in cancer
- Metabolomics and Mass Spectrometry Studies
- Adipose Tissue and Metabolism
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Prostate Cancer Treatment and Research
- Cancer, Stress, Anesthesia, and Immune Response
- Mechanisms of cancer metastasis
- Computational Drug Discovery Methods
- Histone Deacetylase Inhibitors Research
- Mitochondrial Function and Pathology
- Endoplasmic Reticulum Stress and Disease
- Amino Acid Enzymes and Metabolism
University of Florence
2016-2025
Tumour Institute of Tuscany
2014-2016
Enel (Italy)
2014
Breast Cancer Now
2010-2013
Institute of Cancer Research
2010-2013
Cancer Research UK
2013
Royal Marsden Hospital
2013
Breast Cancer Research Foundation
2011
Abstract Lactate is an abundant oncometabolite in the tumor environment. In prostate cancer, cancer-associated fibroblasts (CAF) are major contributors of secreted lactate, which can be taken up by cancer cells to sustain mitochondrial metabolism. However, how lactate impacts transcriptional regulation tumors has yet fully elucidated. Here, we describe a mechanism CAF-secreted able increase expression genes involved lipid metabolism cells. This enhanced intracellular accumulation droplets...
// Luigi Ippolito 1 , Alberto Marini 5 Lorenzo Cavallini Andrea Morandi Laura Pietrovito Gianfranco Pintus 5, 6 Elisa Giannoni Thomas Schrader 2 Martin Puhr 3 Paola Chiarugi 1, 4, * Maria Letizia Taddei 7, Department of Experimental and Clinical Biomedical Sciences, University Florence, Italy Chemistry, Duisburg-Essen, Essen, Germany Urology, Medical Innsbruck, Austria 4 Tuscany Tumor Institute “Center for Research, Transfer High Education DenoTHE”, Laboratory Cell Signaling...
We focused our interest on senescent human‐derived fibroblasts in the progression of prostate cancer. Hypoxic promote cancer aggressiveness by inducing epithelial to mesenchymal transition (EMT) and secreting energy‐rich compounds support cell growth. additionally increase: i) recruitment monocytes their M2‐macrophage polarization, ii) bone marrow‐derived endothelial precursor cells, facilitating vasculogenic ability iii) capillary morphogenesis, proliferation invasion human mature cells. In...
Abstract Most breast cancers at diagnosis are estrogen receptor-positive (ER+) and depend on for growth survival. Blocking biosynthesis by aromatase inhibitors has therefore become a first-line endocrine therapy postmenopausal women with ER+ cancers. Despite providing substantial improvements in patient outcome, inhibitor resistance remains major clinical challenge. The receptor tyrosine kinase, RET, its coreceptor, GFRα1, upregulated subset of cancers, the RET ligand, glial-derived...
// Elisa Giannoni 1 , Maria Letizia Taddei Andrea Morandi Giuseppina Comito Maura Calvani Francesca Bianchini Barbara Richichi 2 Giovanni Raugei Nicholas Wong 3 Damu Tang Paola Chiarugi Department of Experimental and Clinical Biomedical Sciences, University Florence, 50134, Italy Chemistry, 50019, Sesto Fiorentino, Division Nephrology, Medicine, McMaster University, L8N4A6, Hamilton, Ontario, Canada Correspondence to: Chiarugi, e-mail: paola.chiarugi@unifi.it Keywords: pyruvate kinase M2,...
Aromatase inhibitors (AI) have become the first-line endocrine treatment of choice for postmenopausal estrogen receptor-positive (ER(+)) breast cancer patients, but resistance remains a major challenge. Metabolic reprogramming is hallmark and may contribute to drug resistance. Here, we investigated link between altered metabolism AI using AI-resistant sensitive cells, patient tumor samples, AI-sensitive human xenografts. We found that long-term deprivation (LTED), model resistance, was...
// Marta Anna Kowalik 1, * , Giulia Guzzo 2, Andrea Morandi 3, Perra 1 Silvia Menegon 4 Ionica Masgras 2 Elena Trevisan Maria Maddalena Angioni Francesca Fornari 5 Luca Quagliata 6 Giovanna Ledda-Columbano Laura Gramantieri Luigi Terracciano Giordano Paola Chiarugi 3 Rasola Amedeo Columbano Department of Biomedical Sciences, University Cagliari, 09124, Italy Padova, 35122, Experimental and Clinical Florence, 50134 Firenze Tuscan Tumor Institute, Oncology, Torino School Medicine, Candiolo...
Abstract Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic metabolomics analyses of patients’ tumours, metastasis-derived patient-derived xenografts (PDX) isogenic cell lines we demonstrate that fraction metastatic ER BC highly reliant on oxidative phosphorylation (OXPHOS). Treatment by the OXPHOS inhibitor IACS-010759 strongly inhibits tumour growth multiple...
Targeting aromatase deprives ER + breast cancers of estrogens and is an effective therapeutic approach for these tumors. However, drug resistance unmet clinical need. Lipidomic analysis long-term estrogen-deprived (LTED) cancer cells, a model inhibitor resistance, revealed enhanced intracellular lipid storage. Functional metabolic showed that droplets together with peroxisomes, which we to be enriched active in the LTED controlled redox homeostasis conferred adaptability resistant This...
Cellular plasticity confers cancer cells the ability to adapt microenvironmental changes, a fundamental requirement for tumour progression and metastasis. The epithelial mesenchymal transition (EMT) is transcriptional programme associated with increased cell motility stemness. Besides EMT, amoeboid (MAT) has been described during but date, little known about its control involvement in aim of this manuscript investigate (i) profile MAT (ii) study whether acquisition melanoma correlates...
Endocrine therapy (ET) is the standard of care for estrogen receptor-positive (ER+) breast cancers. Despite its efficacy, ∼40% women relapse with ET-resistant (ETR) disease. A global transcription analysis in ETR cells reveals a downregulation neutral and basic amino acid transporter SLC6A14 governed by enhanced miR-23b-3p expression, resulting impaired metabolism. This altered metabolism supported activation autophagy import acidic acids (aspartate glutamate) mediated SLC1A2 transporter....